Abstract: An extrusion system, for example for extruding a food product, that includes: an extruder, which propels extrudate through an outlet of the extruder; and a valve. The valve includes: an inlet, which receives extrudate from the extruder outlet; a main conduit, which extends from the inlet to a main outlet; a dumping conduit, which extends from a junction with the main conduit to a dumping outlet; and a flow control member, which is operable to move between: a plurality of flow controlling positions, in which extrudate is directed to the main outlet, with the flow control member providing, for each flow controlling position, a respective amount of impedance to flow along the main conduit; and a flow diverting position, in which extrudate is directed along the dumping conduit to the dumping outlet.

Abstract: Novel aromatic guanidine compounds having the formula: ##STR1## wherein: R.sub.1 is hydroxyl, methyl or hydroxymethyl and R.sub.2 is hydrogen or methyl, are found to have biological activity. The guanidine compounds and their salts are shown to be active as vasoconstrictor agents and create useful pharmaceutical preparations when deployed with a pharmaceutically acceptable carrier for administration to a host, e.g., man, requiring vasoconstrictive therapy.

Abstract: Resin peptides useful in the preparation of salmon calcitonin are disclosed along with processes for preparing the same. The invention also embraces peptides from which the resin moiety has been cleaved and which are useful in the synthesis of salmon calcitonin together with processes for preparing the cleaved peptides. In general, the processes involve the solid phase synthesis procedures.

Abstract: Novel aromatic guanidine compounds having the formula: ##STR1## wherein: R.sub.1 is hydroxyl, methyl or hydroxymethyl and R.sub.2 is hydrogen or methyl, are found to have biological activity. The guanidine compounds and their salts are shown to be activate as vasoconstrictor agents and create useful pharmaceutical preparations when deployed with a pharmaceutically acceptable carrier for administration to a host, e.g., man, requiring vasoconstrictive therapy.

Abstract: Novel aromatic guanidine compounds having the formula: ##STR1## wherein: R.sub.1 is hydroxyl, methyl or hydroxymethyl and R.sub.2 is hydrogen or methyl, are found to have biological activity. The guanidine compounds and their salts are shown to be active as vasoconstrictor agents and create useful pharmaceutical preparations when deployed with a pharmaceutically acceptable carrier for administration to a host, e.g., man, requiring vasoconstrictive therapy.

Abstract: A pharmaceutical preparation consisting of a pharmaceutical grade carrier and a therapeutically active amount of an aromatic guanidine compound having the formula: ##STR1## or a non-toxic acid addition salt thereof are found to have biologically useful activity. These guanidine preparations and salts are shown to be active as vasoconstrictor agents and obtain useful biological results when deployed with a pharmaceutically acceptable carrier for administration to a host, e.g., man, requiring vasoconstrictive therapy.

Abstract: Tetrahydroisoquinoline compounds represented by the formula: ##SPC1##In whichX is a hydroxy group,Y is a hydroxy group orY taken with X is --O--CH.sub.2 --O--,Z is hydrogen or a hydroxy group,R.sub.1 is hydrogen or an alkyl group of one to four carbon atoms,R.sub.2 is hydrogen, an alkyl group of one to four carbon atoms or phenyl, pyrrolidinomethyl, piperidinomethyl, or morpholinomethyl,R.sub.3 and R.sub.4 each is an alkyl group of one to four carbon atoms or R.sub.3 taken with R.sub.4 and N is pyrrolidinyl, piperidino, morpholino, or 2-(1,2,3,4-tetrahydroisoquinolyl), andn is one or zero,Which compounds are effective as vasodilators, processes for the preparation of these compounds, and intermediate compounds useful in the preparation of such compounds.

Abstract: Pharmaceutical preparations and methods of using the same to treat a host having a condition requiring vasoconstrictive therapy. The preparations comprise a pharmaceutically acceptable carrier and a guanidine compound, or non-toxic acid addition salt thereof, having the structural notation: ##SPC1##Wherein: R.sub.1 is hydrogen or alkyl having 1-4 carbon atoms; R.sub.2 is hydrogen, hydroxy, chloro, fluoro or bromo; and R.sub.3 is hydrogen or the same as R.sub.2 when R.sub.2 is chloro, bromo or fluoro.

Abstract: Compounds having the structure: ##SPC1##In which R.sub.1 and R.sub.2 are alkoxy groups of one to four carbon atoms, R.sub.3 and R.sub.4 each is hydrogen or an alkoxy group of one to four carbon atoms, and R.sub.5 and R.sub.6 each is an alkyl group of one to four carbon atoms or an arylalkyl group such as benzyl or R.sub.5 taken with R.sub.6 and N are pyrrolidinyl, piperidino, or morpholino groups and the pharmaceutically acceptable salts thereof and processes for preparing these compounds. These compounds are useful as vasodilators.

Abstract: A novel aromatic guanidine compound having the formula: ##SPC1##Is found to have biological activity. This guanidine compound and its salts are shown to be active as vasoconstrictor agents and create useful pharmaceutical preparations when deployed with a pharmaceutically acceptable carrier for administration to a host, e.g., man, requiring vasoconstrictive therapy.